Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment (Oncogene, (2021), 40, 44, (6248-6257), 10.1038/s41388-021-02020-z)

Dotan Moskovich, Yael Finkelshtein, Adi Alfandari, Amit Rosemarin, Tzuri Lifschytz, Avivit Weisz, Santanu Mondal, Harinarayana Ungati, Aviva Katzav, Debora Kidron, Govindasamy Mugesh, Martin Ellis, Bernard Lerer, Osnat Ashur-Fabian*

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Fingerprint

Dive into the research topics of 'Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment (Oncogene, (2021), 40, 44, (6248-6257), 10.1038/s41388-021-02020-z)'. Together they form a unique fingerprint.

Medicine & Life Sciences